Literature DB >> 34491628

In Silico Targeting Human Multidrug Transporter ABCG2 in Breast Cancer: Database Screening, Molecular Docking, and Molecular Dynamics Study.

Mahmoud A A Ibrahim1, Esraa A A Badr1, Alaa H M Abdelrahman1, Nahlah Makki Almansour2, Gamal A H Mekhemer1, Ahmed M Shawky3, Mahmoud F Moustafa4,5, Mohamed A M Atia6.   

Abstract

ABCG2 is a substantial member of the ABC transporter superfamily that plays a significant role in multidrug resistance in cancer. Until recently, the 3D structure of ABCG2 has not been resolved, which resulted in the limitation of developing potential ABCG2 inhibitors using structure-based drug discovery. Herein, eMolecules, ChEMBL, and ChEBI databases, containing >25 million compounds, were virtually screened against the ABCG2 transporter in homodimer form. Performance of AutoDock4.2.6 software to predict inhibitor-ABCG2 binding mode and affinity were validated on the basis of available experimental data. The explored databases were filtered based on docking scores. The most potent hits with binding affinities higher than that of experimental bound ligand (MZ29) were then selected and subjected to molecular mechanics minimization, followed by binding energy calculation using molecular mechanics-generalized Born surface area (MM-GBSA) approach. Furthermore, molecular dynamics simulations for 50 ns, followed by MM-GBSA binding energy calculations, were performed for the promising compounds, unveiling eight potential inhibitors with binding affinities <-55.8 kcal/mol. Structural and energetic analyses demonstrated the stability of the eight identified inhibitors over the 50 ns MD simulation. This research sheds light on the potentiality of the identified ABCG2 inhibitors as a therapeutic approach to overcome multidrug resistance cancer therapy.
© 2021 Wiley-VCH GmbH.

Entities:  

Keywords:  ABCG2; Breast cancer; molecular docking; molecular dynamic; multidrug resistance

Mesh:

Substances:

Year:  2021        PMID: 34491628     DOI: 10.1002/minf.202060039

Source DB:  PubMed          Journal:  Mol Inform        ISSN: 1868-1743            Impact factor:   3.353


  4 in total

1.  Naturally occurring plant-based anticancerous candidates as prospective ABCG2 inhibitors: an in silico drug discovery study.

Authors:  Mahmoud A A Ibrahim; Alaa H M Abdelrahman; Esraa A A Badr; Nahlah Makki Almansour; Othman R Alzahrani; Muhammad Naeem Ahmed; Mahmoud E S Soliman; Mohamed Ahmed Naeem; Ahmed M Shawky; Peter A Sidhom; Gamal A H Mekhemer; Mohamed A M Atia
Journal:  Mol Divers       Date:  2022-02-28       Impact factor: 2.943

2.  Exploring Natural Product Activity and Species Source Candidates for Hunting ABCB1 Transporter Inhibitors: An In Silico Drug Discovery Study.

Authors:  Mahmoud A A Ibrahim; Khlood A A Abdeljawaad; Alaa H M Abdelrahman; Laila A Jaragh-Alhadad; Hesham Farouk Oraby; Eslam B Elkaeed; Gamal A H Mekhemer; Gamal A Gabr; Ahmed M Shawky; Peter A Sidhom; Mahmoud E S Soliman; Mahmoud F Moustafa; Paul W Paré; Mohamed-Elamir F Hegazy
Journal:  Molecules       Date:  2022-05-12       Impact factor: 4.927

3.  Synthesis, X-ray diffraction analysis, quantum chemical studies and α-amylase inhibition of probenecid derived S-alkylphthalimide-oxadiazole-benzenesulfonamide hybrids.

Authors:  Bilal Ahmad Khan; Syeda Shamila Hamdani; Muhammad Naeem Ahmed; Shahid Hameed; Muhammad Ashfaq; Ahmed M Shawky; Mahmoud A A Ibrahim; Peter A Sidhom
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

4.  Versisterol, a new endophytic steroid with 3CL protease inhibitory activity from Avicennia marina (Forssk.) Vierh.

Authors:  Marwa Elsbaey; Mahmoud A A Ibrahim; Mohamed-Elamir F Hegazy
Journal:  RSC Adv       Date:  2022-04-26       Impact factor: 4.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.